Use and caregiver-reported efficacy of medical cannabis in children and adolescents in Switzerland.

Zürcher, Kathrin; Dupont, Carole; Weber, Peter; Grunt, Sebastian; Wilhelm, Ilca; Eigenmann, Daniela E; Reichmuth, Martina L.; Fankhauser, Manfred; Egger, Matthias; Fenner, Lukas (2021). Use and caregiver-reported efficacy of medical cannabis in children and adolescents in Switzerland. (In Press). European journal of pediatrics Springer-Verlag 10.1007/s00431-021-04202-z

[img]
Preview
Text
Z_rcher_EurJPediatrics_2021_epub.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (2MB) | Preview

Evidence on the use and efficacy of medical cannabis for children is limited. We examined clinical and epidemiological characteristics of medical cannabis treatment and caregiver-reported effects in children and adolescents in Switzerland. We collected clinical data from children and adolescents (< 18 years) who received Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of the two between 2008 and 2019 in Switzerland. Out of 205 contacted families, 90 agreed to participate. The median age at the first prescription was 11.5 years (interquartile range (IQR) 6-16), and 32 patients were female (36%). Fifty-one (57%) patients received CBD only and 39 (43%) THC. Patients were more likely to receive THC therapy if one of the following symptoms or signs were present: spasticity, pain, lack of weight gain, vomiting, or nausea, whereas seizures were the dominant indication for CBD therapy. Improvements were reported in 59 (66%) study participants. The largest treatment effects were reported for pain, spasticity, and frequency of seizures in participants treated with THC, and for those treated with pure CBD, the frequency of seizures. However, 43% of caregivers reported treatment interruptions, mainly because of lack of improvement (56%), side effects (46%), the need for a gastric tube (44%), and cost considerations (23%).Conclusions: The effects of medical cannabis in children and adolescents with chronic conditions are unknown except for rare seizure disorders, but the caregiver-reported data analysed here may justify trials of medical cannabis with standardized concentrations of THC or CBD to assess its efficacy in the young. What is Known: • The use of medical cannabis (THC and CBD) to treat a variety of diseases among children and adolescents is increasing. • In contrast to adults, there is no evidence to support the use of medical cannabis to treat chronic pain and spasticity in children, but substantial evidence to support the use of CBD in children with rare seizure disorders. What is New: • This study provides important insights into prescription practices, dosages, and treatment outcomes in children and adolescents using medical cannabis data from a real-life setting. • The effects of medical cannabis in children and adolescents with chronic conditions shown in our study support trials of medical cannabis for chronic conditions.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine
04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic and Policlinic for Anaesthesiology and Pain Therapy
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)

UniBE Contributor:

Zürcher, Kathrin; Dupont, Carole; Grunt, Sebastian; Wilhelm-Pahl, Ilca Ricarda; Reichmuth, Martina Larissa; Egger, Matthias and Fenner, Lukas

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0340-6199

Publisher:

Springer-Verlag

Funders:

[4] Swiss National Science Foundation

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

28 Jul 2021 15:16

Last Modified:

29 Jul 2021 19:25

Publisher DOI:

10.1007/s00431-021-04202-z

PubMed ID:

34309706

Additional Information:

Open Access funding provided by Universität Bern.

Uncontrolled Keywords:

Cannabidiol Children Chronic conditions Medical cannabis Seizures Tetrahydrocannabinol Treatment

BORIS DOI:

10.48350/157818

URI:

https://boris.unibe.ch/id/eprint/157818

Actions (login required)

Edit item Edit item
Provide Feedback